Discovery & Imaging Technical Resources | Charles River

discovery & imaging 

With the addition of MIR Preclinical Services, Piedmont Research Center and Cerebricon, Charles River further expanded its discovery expertise in the key therapeutic areas of oncology, inflammation and CNS, all complemented by cutting-edge in vivo imaging capabilities. To learn more about the advantages imaging can have on drug discovery and development, ask for a replay of our webinar entitled Effective Use of Translational Imaging for Early Indication of Treatment Response.

Click on the links below for additional technical information from Charles River Discovery & Imaging Services.

discovery & imaging services

Technical Sheets
The Role of Biomarkers in Drug Discovery and Development
Poster Presentations
Imaging an inflammatory response using 19F-MRI 
Poster originally presented at the 15th International Inflammation Research Association Conference (Sept 2008)
Diffusion MRI Early Prediction of Survival Using Solvent Facilitated Perfusion of BCNU in a Rat Model of Glioma
Poster originally presented at the American Association for Cancer Research 2006 Annual Meeting
Efficacy of Temozolomide in a Transgenic Model of Glioma: MRI Determined Tumor Growth Inhibition and Diffusion Response are Predictive of Survival
Poster originally presented at the American Association for Cancer Research 2006 Annual Meeting
Intratumoral Injection of BCNU in Ethanol (DTI-015) and BCNU in Ethanol/PEG400 Cure Subcutaneous C26 Tumors
Poster originally presented at the American Association for Cancer Research 2006 Annual Meeting
MRI Predicts Tumor Grade and Survival in a tv-a Transgenic Model of Glioma
Poster originally presented at the American Association for Cancer Research 2005 Annual Meeting
MRI Determination of Temozolamide Treatment Response in a tv-a Transgenic Model of Glioma
Poster originally presented at the American Association for Cancer Research 2005 Annual Meeting
Evaluation of MRI in a Mouse Model of Liver Metastasis
Poster originally presented at the American Association for Cancer Research 2005 Annual Meeting
In vivo Micro-CT of Mouse Lungs Without Respiratory Gating
Poster originally presented at the American Association for Cancer Research 2005 Annual Meeting
In vivo Imaging of a Mouse Model of PC-3 Bone Metastasis
Poster originally presented at the American Association for Cancer Research 2005 Annual Meeting
High-throughput MRI in the use and development of preclinical mouse tumor models
Poster originally presented at the American Association for Cancer Research 2005 Annual Meeting
High field MRI characterization of tumor growth kinetics, vascularity and cellularity in a PDGF-driven tv-a mouse model of glioma
Poster originally presented at the American Association for Cancer Research 2004 Annual Meeting
Diffusion MRI in preclinical drug testing: An early surrogate marker for efficacy in subcutaneous human tumor xenografts
Poster originally presented at the American Association for Cancer Research 2004 Annual Meeting
Assessment of treatment efficacy in preclinical drug testing using magnetic resonance imaging
Poster originally presented at the American Association for Cancer Research 2004 Annual Meeting
Articles
Future Image
Future Pharmaceuticals, Nov 2008
Article Abstracts
Structure-guided inhibitor design for human FAAH by interspecies active site conversion
Proceedings of the National Academy of Sciences of the United States of America, 2008 Sep 2;105(32):12820-4.
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma
Clinical Cancer Research, 13(10):2897-2904, May 15,2007.
Vascular targeted nanoparticles for imaging and treatment of brain tumors
Clinical Cancer Research, 12(22):6677-86, November 15, 2006.
High-throughput magnetic resonance imaging in mice for phenotyping and therapeutic evaluation
Current Opinion in Chemical Biology, 2005 Aug;9(4):413-420.
Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4
Journal of Medicinal Chemistry, 48(7):2371-2387, April 7, 2005
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
Molecular Cancer Therapeutics, 3(11):1427-37, November 2004.
Use of Magnetic Resonance Imaging for Evaluation of Treatment Response
Appears in "Mouse Models of Human Cancer”
A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI
Molecular Imaging, 2(4):324-32, 2003
Evaluation of cancer therapy using diffusion magnetic resonance imaging
Molecular Cancer Therapeutics, 2(6):581-7, 2003.

For additional technical information or details about any of our products and services, contact us at askcharlesriver@crl.com.
Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

(Country Code)+800.3195.3430
askcharlesriver@crl.com

view all

News & Events

view all
mai 13 - High-Throughput Screening for CNS ...
mai 08 - Comparability Studies for Monoclon...
mai 28-juin 01 - Kobe, Japan - Joint Meering of the International Bone and Mineral Soci...
mai 23-mai 23 - East Lansing, Michigan, USA - The Ins and Outs of Transgenic Colongy Ma...

Charles River Laboratories, Inc.